Faculty
Oncology Division
Alphabetical list (active faculty):   
Mateusz Opyrchal

Mateusz Opyrchal, MD, PhD

Associate Professor

Department of Medicine

Oncology Division

Medical Oncology

Clinical Interests

  • Breast cancer

Contact

  • 314-747-7510 (office)
  • 314-362-7086 (fax)
  • Division of Oncology
    Mail Stop 8056-0029-11
    Washington University
    660 South Euclid Avenue
    St. Louis, MO 63110
  • Room 11412 Mid-Campus Center (office)

Peer-reviewed Publications

  • A Phase I Study of the Anaplastic Lymphoma Kinase Inhibitor Ceritinib in Combination With Gemcitabine-Based Chemotherapy in Patients With Advanced Solid Tumors
    Fountzilas C, Adjei A, Opyrchal M, Evans R, Ghasemi M, Attwood K, Groman A, Bshara W, Goey A, Wilton J, Ma WW, Iyer R
    Int J Cancer 2021 Dec 15;149(12):2063-2074
  • Phase 1 Study Combining Alisertib With Nab-Paclitaxel in Patients With Advanced Solid Malignancies
    Lim KH, Opyrchal M, Acharya A, Boice N, Wu N, Gao F, Webster J, Lockhart AC, Waqar SN, Govindan R, Morgensztern D, Picus J, Tan BR, Baggstrom MQ, Maher CA, Wang-Gillam A
    Eur J Cancer 2021 Sep;154:102-110
  • Immunogenomic Profiling and Pathological Response Results From a Clinical Trial of Docetaxel and Carboplatin in Triple-Negative Breast Cancer
    Ademuyiwa FO, Chen I, Luo J, Rimawi MF, Hagemann IS, Fisk B, Jeffers G, Skidmore ZL, Basu A, Richters M, Ma CX, Weilbaecher K, Davis J, Suresh R, Peterson LL, Bose R, Bagegni N, Rigden CE, Frith A, Rearden TP, Hernandez-Aya LF, Roshal A, Clifton K, Opyrchal M, Akintola-Ogunremi O, Lee BH, Ferrando-Martinez S, Church SE, Anurag M, Ellis MJ, Gao F, Gillanders W, Griffith OL, Griffith M
    Breast Cancer Res Treat 2021 Aug;189(1):187-202
  • Cytotoxic T-Lymphocyte Infiltration and Chemokine Predict Long-Term Patient Survival Independently of Tumor Mutational Burden in Triple-Negative Breast Cancer
    Katsuta E, Yan L, Opyrchal M, Kalinski P, Takabe K
    Ther Adv Med Oncol 2021 Apr 5;13:17588359211006680
  • Mutation Profile Differences in Younger and Older Patients With Advanced Breast Cancer Using Circulating Tumor DNA (CtDNA)
    Clifton K, Luo J, Tao Y, Saam J, Rich T, Roshal A, Frith A, Rigden C, Ademuyiwa F, Weilbaecher K, Hernandez-Aya L, Peterson LL, Bagegni N, Suresh R, Bose R, Opyrchal M, Wildes TM, Ma C
    Breast Cancer Res Treat 2021 Feb;185(3):639-646
  • Entinostat Plus Pembrolizumab in Patients With Metastatic NSCLC Previously Treated With Anti-PD-(L)1 Therapy
    Hellmann MD, Janne PA, Opyrchal M, Hafez N, Raez LE, Gabrilovich DI, Wang F, Trepel JB, Lee MJ, Yuno A, Lee S, Brouwer S, Sankoh S, Wang L, Tamang D, Schmidt EV, Meyers ML, Ramalingam SS, Shum E, Ordentlich P
    Clin Cancer Res 2021 Feb 15;27(4):1019-1028
  • Outcome of Everolimus-Based Therapy in Hormone-Receptor-Positive Metastatic Breast Cancer Patients After Progression on Palbociclib
    Dhakal A, Antony Thomas R, Levine EG, Brufsky A, Takabe K, Hanna MG, Attwood K, Miller A, Khoury T, Early AP, Soniwala S, O'Connor T, Opyrchal M
    Breast Cancer (Auckl) 2020 Jul 23;14:1178223420944864
  • Contribution of Immune Cells to Glucocorticoid Receptor Expression in Breast Cancer
    Gandhi S, Elkhanany A, Oshi M, Dai T, Opyrchal M, Mohammadpour H, Repasky EA, Takabe K
    Int J Mol Sci 2020 Jun 30;21(13)
  • High MYC mRNA Expression Is More Clinically Relevant Than MYC DNA Amplification in Triple-Negative Breast Cancer
    Katsuta E, Yan L, Takeshita T, McDonald KA, Dasgupta S, Opyrchal M, Takabe K
    Int J Mol Sci 2019 Dec 28;21(1)
  • Pralatrexate in Combination With Oxaliplatin in Advanced Esophagogastric Cancer: A Phase II Trial With Predictive Molecular Correlates
    Malhotra U, Mukherjee S, Fountzilas C, Boland P, Miller A, Patnaik S, Attwood K, Yendamuri S, Adjei A, Kannisto E, Opyrchal M, Bushunow P, Loud P, Iyer R, Khushalani N
    Mol Cancer Ther 2020 Jan;19(1):304-311
  • Primary and Secondary Breast Angiosarcoma: Single Center Report and a Meta-Analysis
    Abdou Y, Elkhanany A, Attwood K, Ji W, Takabe K, Opyrchal M
    Breast Cancer Res Treat 2019 Dec;178(3):523-533
  • Oncologist Uptake of Comprehensive Genomic Profile Guided Targeted Therapy
    Nesline MK, DePietro P, Dy GK, Early A, Papanicolau-Sengos A, Conroy JM, Lenzo FL, Glenn ST, Chen H, Grand'Maison A, Boland P, Ernstoff MS, Puzanov I, Edge S, Akers S, Opyrchal M, Chatta G, Odunsi K, Frederick P, Lele S, Gardner M, Morrison C
    Oncotarget 2019 Jul 23;10(45):4616-4629
  • Chimeric Antigen Receptor-T Cells for Targeting Solid Tumors: Current Challenges and Existing Strategies
    Springuel L, Lonez C, Alexandre B, Van Cutsem E, Machiels JH, Van Den Eynde M, Prenen H, Hendlisz A, Shaza L, Carrasco J, Canon JL, Opyrchal M, Odunsi K, Rottey S, Gilham DE, Flament A, Lehmann FF
    BioDrugs 2019 Oct;33(5):515-537
  • Recruitment of Intratumoral CD103(+) Dendritic Cells by a CXCR4 Antagonist-Armed Virotherapy Enhances Antitumor Immunity
    Mistarz A, Komorowski MP, Graczyk MA, Gil M, Jiang A, Opyrchal M, Rokita H, Odunsi KO, Kozbor D
    Mol Ther Oncolytics 2019 Jul 3;14:233-245
  • Tumor Heterogeneity Correlates With Less Immune Response and Worse Survival in Breast Cancer Patients
    McDonald KA, Kawaguchi T, Qi Q, Peng X, Asaoka M, Young J, Opyrchal M, Yan L, Patnaik S, Otsuji E, Takabe K
    Ann Surg Oncol 2019 Jul;26(7):2191-2199
  • Treatment Recommendations to Cancer Patients in the Context of FDA Guidance for Next Generation Sequencing
    Dy GK, Nesline MK, Papanicolau-Sengos A, DePietro P, LeVea CM, Early A, Chen H, Grand'Maison A, Boland P, Ernstoff MS, Edge S, Akers S, Opyrchal M, Chatta G, Odunsi K, Pabla S, Conroy JM, Glenn ST, DeFedericis HT, Burgher B, Andreas J, Giamo V, Qin M, Wang Y, Kanehira K, Lenzo FL, Frederick P, Lele S, Galluzzi L, Kuvshinoff B, Morrison C
    BMC Med Inform Decis Mak 2019 Jan 18;19(1):14
  • Efficacy of Palbociclib Combinations in Hormone Receptor-Positive Metastatic Breast Cancer Patients After Prior Everolimus Treatment
    Dhakal A, Matthews CM, Levine EG, Salerno KE, Zhang F, Takabe K, Early AP, Edge SB, O'Connor T, Khoury T, Young JS, Opyrchal M
    Clin Breast Cancer 2018 Dec;18(6):e1401-e1405
  • The Role of Programmed Death Ligand-1 and Tumor-Infiltrating Lymphocytes in Breast Cancer Overexpressing HER2 Gene
    Li Y, Opyrchal M, Yao S, Peng X, Yan L, Jabbour H, Khoury T
    Breast Cancer Res Treat 2018 Jul;170(2):293-302
  • Phase I Trial to Evaluate the Addition of Alisertib to Fulvestrant in Women With Endocrine-Resistant, ER+ Metastatic Breast Cancer
    Haddad TC, D'Assoro A, Suman V, Opyrchal M, Peethambaram P, Liu MC, Goetz MP, Ingle JN
    Breast Cancer Res Treat 2018 Apr;168(3):639-647
  • The Role of Skin Ulceration in Breast Carcinoma Staging and Outcome
    Khoury T, Gaudioso C, Fang YV, Sanati S, Opyrchal M, Desouki MM, Karabakhtsian RG, Li Z, Wang D, Yan L, Jacobson R
    Breast J 2018 Jan;24(1):41-50
  • Prognostic Significance of Stromal Versus Intratumoral Infiltrating Lymphocytes in Different Subtypes of Breast Cancer Treated With Cytotoxic Neoadjuvant Chemotherapy
    Khoury T, Nagrale V, Opyrchal M, Peng X, Wang D, Yao S
    Appl Immunohistochem Mol Morphol 2018 Sep;26(8):523-532
  • Molecular Targeting of the Aurora-A/SMAD5 Oncogenic Axis Restores Chemosensitivity in Human Breast Cancer Cells
    Opyrchal M, Gil M, Salisbury JL, Goetz MP, Suman V, Degnim A, McCubrey J, Haddad T, Iankov I, Kurokawa CB, Shumacher N, Ingle JN, Galanis E, D'Assoro AB
    Oncotarget 2017 Sep 1;8(53):91803-91816
  • A Rare Case of S310F Somatic ERBB2 Mutation in a HER2-Nonamplified Breast Cancer
    Jasra S, Opyrchal M, Norton L, Mehta R
    Clin Breast Cancer 2017 Feb;17(1):e37-e41
  • Reprogramming Antitumor Immunity Against Chemoresistant Ovarian Cancer by a CXCR4 Antagonist-Armed Viral Oncotherapy
    Komorowski MP, McGray AR, Kolakowska A, Eng K, Gil M, Opyrchal M, Litwinska B, Nemeth MJ, Odunsi KO, Kozbor D
    Mol Ther Oncolytics 2016 Dec 14;3:16034
  • A Case of Metaplastic Breast Cancer With Prolonged Response to Single Agent Liposomal Doxorubicin
    Hamad L, Khoury T, Vona K, Nestico J, Opyrchal M, Salerno KE
    Cureus 2016 Jan 11;8(1):e454
  • Comprehensive Histologic Scoring to Maximize the Predictability of Pathology-Generated Equation of Breast Cancer Oncotype DX Recurrence Score
    Khoury T, Huang X, Chen X, Wang D, Liu S, Opyrchal M
    Appl Immunohistochem Mol Morphol 2016 Nov/Dec;24(10):703-711
  • Exceptional Clinical Response to BRAF-Targeted Therapy in a Patient With Metastatic Sarcoma
    Mitsis D, Opyrchal M, Zhao Y, Kane Iii JM, Cheney R, Salerno KE
    Cureus 2015 Dec 28;7(12):e439
  • CXCL12/CXCR4 Blockade by Oncolytic Virotherapy Inhibits Ovarian Cancer Growth by Decreasing Immunosuppression and Targeting Cancer-Initiating Cells
    Gil M, Komorowski MP, Seshadri M, Rokita H, McGray AJ, Opyrchal M, Odunsi KO, Kozbor D
    J Immunol 2014 Nov 15;193(10):5327-37
  • Inhibition of Cdk2 Kinase Activity Selectively Targets the CD44(+)/CD24(-)/Low Stem-Like Subpopulation and Restores Chemosensitivity of SUM149PT Triple-Negative Breast Cancer Cells
    Opyrchal M, Salisbury JL, Iankov I, Goetz MP, McCubrey J, Gambino MW, Malatino L, Puccia G, Ingle JN, Galanis E, D'Assoro AB
    Int J Oncol 2014 Sep;45(3):1193-9
  • Aurora-A Mitotic Kinase Induces Endocrine Resistance Through Down-Regulation of ERalpha Expression in Initially ERalpha+ Breast Cancer Cells
    Opyrchal M, Salisbury JL, Zhang S, McCubrey J, Hawse J, Goetz MP, Lomberk GA, Haddad T, Degnim A, Lange C, Ingle JN, Galanis E, D'Assoro AB
    PLoS One 2014 May 9;9(5):e96995
  • The Mitotic Kinase Aurora--A Promotes Distant Metastases by Inducing Epithelial-To-Mesenchymal Transition in ERalpha(+) Breast Cancer Cells
    D'Assoro AB, Liu T, Quatraro C, Amato A, Opyrchal M, Leontovich A, Ikeda Y, Ohmine S, Lingle W, Suman V, Ecsedy J, Iankov I, Di Leonardo A, Ayers-Inglers J, Degnim A, Billadeau D, McCubrey J, Ingle J, Salisbury JL, Galanis E
    Oncogene 2014 Jan 30;33(5):599-610
  • Inhibition of Rho-Associated Coiled-Coil-Forming Kinase Increases Efficacy of Measles Virotherapy
    Opyrchal M, Allen C, Msaouel P, Iankov I, Galanis E
    Cancer Gene Ther 2013 Nov;20(11):630-7
  • Oncolytic Measles Virus Strains Have Significant Antitumor Activity Against Glioma Stem Cells
    Allen C, Opyrchal M, Aderca I, Schroeder MA, Sarkaria JN, Domingo E, Federspiel MJ, Galanis E
    Gene Ther 2013 Apr;20(4):444-9
  • Dephosphorylation of HuR Protein During Alphavirus Infection Is Associated With HuR Relocalization to the Cytoplasm
    Dickson AM, Anderson JR, Barnhart MD, Sokoloski KJ, Oko L, Opyrchal M, Galanis E, Wilusz CJ, Morrison TE, Wilusz J
    J Biol Chem 2012 Oct 19;287(43):36229-38
  • Effective Radiovirotherapy for Malignant Gliomas by Using Oncolytic Measles Virus Strains Encoding the Sodium Iodide Symporter (MV-NIS)
    Opyrchal M, Allen C, Iankov I, Aderca I, Schroeder M, Sarkaria J, Galanis E
    Hum Gene Ther 2012 Apr;23(4):419-27
  • Translational Research in Oncolytic Measles Virotherapy: Early Discoveries and Future Steps
    Msaouel P, Opyrchal M, Galanis E
    Future Microbiol 2011 Feb;6(2):125-8
  • Spontaneous Tumor Lysis Syndrome in the Setting of B-Cell Lymphoma
    Opyrchal M, Figanbaum T, Ghosh A, Rajkumar V, Caples S
    Case Rep Med 2010;2010:610969
  • Phase I Clinical Trial of Locoregional Administration of the Oncolytic Adenovirus ONYX-015 in Combination With Mitomycin-C, Doxorubicin, and Cisplatin Chemotherapy in Patients With Advanced Sarcomas
    Opyrchal M, Aderca I, Galanis E
    Methods Mol Biol 2009;542:705-17
  • The 3' Untranslated Region of Sindbis Virus Represses Deadenylation of Viral Transcripts in Mosquito and Mammalian Cells
    Garneau NL, Sokoloski KJ, Opyrchal M, Neff CP, Wilusz CJ, Wilusz J
    J Virol 2008 Jan;82(2):880-92
  • A Cell-Free mRNA Stability Assay Reveals Conservation of the Enzymes and Mechanisms of mRNA Decay Between Mosquito and Mammalian Cell Lines
    Opyrchal M, Anderson JR, Sokoloski KJ, Wilusz CJ, Wilusz J
    Insect Biochem Mol Biol 2005 Dec;35(12):1321-34
  • Assessing Messenger RNA Decapping in Cellular Extracts
    Bergman N, Milone J, Bates EJ, Opyrchal M, Bellofatto V, Wilusz J
    Methods Mol Biol 2004;257:181-92
  • Analysis of the Products of mRNA Decapping and 3'-To-5' Decay by Denaturing Gel Electrophoresis
    Bergman N, Opyrchal M, Bates EJ, Wilusz J
    RNA 2002 Jul;8(7):959-65

Reviews

  • Clinical Trials With Oncolytic Measles Virus: Current Status and Future Prospects
    Msaouel P, Opyrchal M, Dispenzieri A, Peng KW, Federspiel MJ, Russell SJ, Galanis E
    Curr Cancer Drug Targets 2018;18(2):177-187
  • Immune Checkpoint Inhibitors in Triple Negative Breast Cancer
    Budhathoki N, Dhakal A, Opyrchal M
    Theranostics of Cancer Research 2017 Aug 21
  • Aurora A Kinase Novel Therapeutic Target in Treatment of Breast Cancer?
    Opyrchal M, Sangameswaran DG, Khoury T, Boland PM, Galanis E. Haddad TC, D’Assoro A
    AJHO 2015 Dec
  • Aurora Kinase A and Gastrointestinal Malignancies
    Pokuri VK, Opyrchal M, Boland PM
    Intl J Cancer Res Mol Mech 2015 Sep;1(3)
  • Multi-Targeted Kinase Inhibitor Sorafenib and Its Future
    Gil M, Weroha SJ, Iyer R, Opyrchal M
    Cancer Chemotherapy Reviews 2015 Jan-Mar;10(1)
  • The Potential of Antibody Drug Conjugates in the Treatment of Breast Cancer
    Gaertner K, Sangameswaran DG, Khoury T, Young J, Opyrchal M
    J Targeted Ther in Cancer 2015 Feb:36-43
  • Oncolytic Measles Virus Strains as Novel Anticancer Agents
    Msaouel P, Opyrchal M, Domingo Musibay E, Galanis E
    Expert Opin Biol Ther 2013 Apr;13(4):483-502

Editorials

  • Reducing Errors During Patient-Care Handoffs
    Opyrchal, M
    Oncology Fellows 2012 Dec/Jan;3(4)